Literature DB >> 9022561

Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group.

P K Whelton1, S K Kumanyika, N R Cook, J A Cutler, N O Borhani, C H Hennekens, L H Kuller, H Langford, D W Jones, S Satterfield, N L Lasser, J D Cohen.   

Abstract

Phase 1 of the Trials of Hypertension Prevention was conducted in 2182 adults, aged 35-54 y, with diastolic blood pressure of 80-89 mm Hg to test the feasibility and blood pressure-lowering effects of seven nonpharmacologic interventions (weight loss, sodium reduction, stress management, and supplementation with calcium, magnesium, potassium, and fish oil). At 6 and 18 mo, weight loss and sodium reduction were well-tolerated and produced significant declines in systolic and diastolic blood pressures (-2.9/-2.4 and -2.1/-1.2 mm Hg for weight loss and sodium reduction, respectively, at 18 mo). None of the other interventions lowered blood pressure significantly at either the 6- or 18-mo follow-up visits. These results suggest that both weight loss and sodium reduction provide an effective means to prevent hypertension. The long-term effects of both of these interventions are being tested in phase 2 of the trial.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9022561     DOI: 10.1093/ajcn/65.2.652S

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  37 in total

Review 1.  Quality of life with nonpharmacologic treatment of hypertension.

Authors:  J P Roel; C L Hildebrant; R H Grimm
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 2.  Nonesterified fatty acids in blood pressure control and cardiovascular complications.

Authors:  B M Egan; E L Greene; T L Goodfriend
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

Review 3.  Reduced or modified dietary fat for preventing cardiovascular disease.

Authors:  Lee Hooper; Carolyn D Summerbell; Rachel Thompson; Deirdre Sills; Felicia G Roberts; Helen J Moore; George Davey Smith
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 4.  Can We End the Salt Wars With a Randomized Clinical Trial in a Controlled Environment?

Authors:  Daniel W Jones; Friedrich C Luft; Paul K Whelton; Michael H Alderman; John E Hall; Eric D Peterson; Robert M Califf; David A McCarron
Journal:  Hypertension       Date:  2018-05-07       Impact factor: 10.190

Review 5.  Systematic review of long term effects of advice to reduce dietary salt in adults.

Authors:  Lee Hooper; Christopher Bartlett; George Davey Smith; Shah Ebrahim
Journal:  BMJ       Date:  2002-09-21

Review 6.  Role of dietary therapies in the prevention and treatment of hypertension.

Authors:  Viresh Mohanlal; Afshin Parsa; Matthew R Weir
Journal:  Nat Rev Nephrol       Date:  2012-05-15       Impact factor: 28.314

7.  Stress Reduction in the Prevention of Left Ventricular Hypertrophy: A Randomized Controlled Trial of Transcendental Meditation and Health Education in Hypertensive African Americans.

Authors:  Robert H Schneider; Hector F Myers; Komal Marwaha; Maxwell A Rainforth; John W Salerno; Sanford I Nidich; Carolyn Gaylord-King; Charles N Alexander; Keith C Norris
Journal:  Ethn Dis       Date:  2019-10-17       Impact factor: 1.847

Review 8.  Role of dietary salt and potassium intake in cardiovascular health and disease: a review of the evidence.

Authors:  Kristal J Aaron; Paul W Sanders
Journal:  Mayo Clin Proc       Date:  2013-09       Impact factor: 7.616

9.  The effects of weight loss and salt reduction on visit-to-visit blood pressure variability: results from a multicenter randomized controlled trial.

Authors:  Keith M Diaz; Paul Muntner; Emily B Levitan; Michael D Brown; Dianne M Babbitt; Daichi Shimbo
Journal:  J Hypertens       Date:  2014-04       Impact factor: 4.844

10.  DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre.

Authors:  Y Al-Solaiman; A Jesri; W K Mountford; D T Lackland; Y Zhao; B M Egan
Journal:  J Hum Hypertens       Date:  2009-07-23       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.